Learn About Smoldering Multiple Myeloma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
MD Anderson
Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski and is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.
Bruno Paiva practices in Pamplona, Spain. Mr. Paiva and is rated as an Elite expert by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Aspiration, and Bone Marrow Transplant.
Dana-Farber Cancer Institute, Inc.
Nikhil Munshi is an Oncologist in Boston, Massachusetts. Dr. Munshi and is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Castleman Disease, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration. Dr. Munshi is currently accepting new patients.
Summary: The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of high-risk monoclonal gammopathy of undetermined significance (HR-MGUS) and non high-risk smoldering multiple myeloma (NHR-SMM). This requires understanding the safety and tolerability of the study drug (how the body reacts to linvoseltamab) as well as the effectiven...
Summary: This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. The study will have a dose-finding part and a dose-expansion part. The maximum number of enrolled patients will be 30 with 18 patients for the dose-finding part an...